Amendment to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A ~~non-human~~ model mouse ~~animal of Goodpasture's syndrome characterized in that a non-human animal whose function of immunoglobulin Fcγ receptor IIB gene is deficient on its chromosome is obtained by immunizing with type IV collagen~~ showing at least one of the symptoms selected from the group consisting of diffuse alveolar hemorrhage, glomerulonephritis, and the appearance of antikidney glomerular basement membrane antibody, wherein the model mouse is obtained by immunizing with type IV collagen a homozygous and nonchimeric mouse whose endogenous genes that code for FcγRIIB are inactivated by genetic mutation such as destruction, deficiency, or substitution and whose function of expressing FcγRIIB is impaired.

2. (Cancelled)

3. (Currently amended) A method for screening a remedy for ~~Goodpasture's syndrome characterized in that test substances are administered to a non-human animal whose function of immunoglobulin Fcγ receptor IIB gene is deficient on its chromosome before or after immunizing or at the same time the said non-human animal is immunized with type IV collagen, and the severity of the expression of Goodpasture's syndrome as an index is evaluated.~~ at least one of the diseases selected from the group consisting of diffuse alveolar

hemorrhage, glomerulonephritis, and the appearance of antikidney glomerular basement membrane antibody, comprising the steps of:

1) administering a test substance to a model mouse showing at least one of the symptoms selected from the group consisting of diffuse alveolar hemorrhage, glomerulonephritis, and the appearance of antikidney glomerular basement membrane antibody, wherein the model mouse is obtained by immunizing with type IV collagen a homozygous and nonchimeric mouse whose endogenous genes that code for FcRIIB are inactivated by genetic mutation such as destruction, deficiency, or substitution,

2) determining at least one exhibition among diffuse alveolar hemorrhage, glomerulonephritis, and the appearance of antikidney glomerular basement membrane antibody,

3) performing a comparative evaluation with a wild-type mouse used as control.

4-11. (Cancelled)